Artiva Biotherapeutics, Inc. (ARTV) · Insider trading
What Artiva Biotherapeutics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$109.12M
2 insiders, 21 trades
Sold, 12 months
$2.52M
5 insiders, 23% under a plan
Net, 12 months
+$106.60M
bought less sold
Latest filing
2026-10-07
filings read to 2026-10-20
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Ra Capital Healthcare Fund LPDirector, 10% owner | $92.62M | – | 19 | 2026-07-31 | – |
| Gc Corp.10% owner | $16.50M | – | 2 | 2026-05-11 | 4,391,969 |
| Aslan FredDirector, Chief Executive Officer | – | $2.04M | 9 | 2026-10-06 | 1,519,606 |
| Horan ChristopherChief Tech Operations Officer | – | $249,469 | 3 | 2026-10-05 | 312,744 |
| Bush JenniferCOO, CLO, Compliance Officer | – | $230,069 | 3 | 2026-10-05 | 366,159 |
| Banerjee SubhashisChief Medical Officer | – | $187,088 | 5 | 2026-10-05 | 169,848 |
| Raymon HeatherSVP, Research and Development | – | $27,886 | 1 | 2026-05-19 | 148,228 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Aslan FredDirector, Chief Executive Officer | Saleplan | 23,463 | 7.20 | $168,880 | 1,519,606 | Form 4 |
| 2026-10-05 | Aslan FredDirector, Chief Executive Officer | Sale | 61,696 | 6.84 | $421,828 | 1,543,069 | Form 4 |
| 2026-10-05 | Banerjee SubhashisChief Medical Officer | Sale | 1,099 | 6.84 | $7,514 | 169,848 | Form 4 |
| 2026-10-05 | Bush JenniferCOO, CLO, Compliance Officer | Sale | 8,370 | 6.84 | $57,227 | 366,159 | Form 4 |
| 2026-10-05 | Horan ChristopherChief Tech Operations Officer | Sale | 10,340 | 6.84 | $70,697 | 312,744 | Form 4 |
| 2026-09-08 | Aslan FredDirector, Chief Executive Officer | Saleplan | 23,429 | 10.92 | $255,845 | 1,449,765 | Form 4 |
| 2026-09-03 | Aslan FredDirector, Chief Executive Officer | Sale | 61,888 | 11.16 | $690,670 | 1,473,194 | Form 4 |
| 2026-09-03 | Banerjee SubhashisChief Medical Officer | Sale | 1,100 | 11.16 | $12,276 | 140,947 | Form 4 |
| 2026-09-03 | Bush JenniferCOO, CLO, Compliance Officer | Sale | 8,391 | 11.16 | $93,644 | 329,529 | Form 4 |
| 2026-09-03 | Horan ChristopherChief Tech Operations Officer | Sale | 10,366 | 11.16 | $115,685 | 283,084 | Form 4 |
| 2026-08-27 | Banerjee SubhashisChief Medical Officer | Saleplan | 8,222 | 12.01 | $98,746 | 142,047 | Form 4 |
| 2026-08-18 | Banerjee SubhashisChief Medical Officer | Saleplan | 429 | 12.00 | $5,148 | 144,963 | Form 4 |
| 2026-07-31 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 24,944 | 9.93 | $247,694 | 17,329,570 | Form 4 |
| 2026-07-29 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 20,824 | 9.99 | $208,032 | 17,304,626 | Form 4 |
| 2026-07-24 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 41,319 | 9.99 | $412,777 | 17,283,802 | Form 4 |
| 2026-07-23 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 59,880 | 9.96 | $596,405 | 17,242,483 | Form 4 |
| 2026-07-22 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 84,124 | 9.93 | $835,351 | 17,182,603 | Form 4 |
| 2026-07-21 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 120,582 | 9.55 | $1.15M | 17,098,479 | Form 4 |
| 2026-07-17 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 7,882 | 8.95 | $70,544 | 16,977,927 | Form 4 |
| 2026-07-16 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 152,472 | 8.93 | $1.36M | 16,970,045 | Form 4 |
| 2026-07-13 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 6,522 | 8.94 | $58,307 | 16,817,543 | Form 4/A |
| 2026-07-10 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 15,102 | 8.97 | $135,465 | 16,811,021 | Form 4 |
| 2026-06-26 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 1,876 | 8.98 | $16,846 | 16,795,919 | Form 4 |
| 2026-06-25 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 31,000 | 8.88 | $275,280 | 16,794,043 | Form 4 |
| 2026-06-16 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 124,893 | 8.89 | $1.11M | 16,763,043 | Form 4 |
| 2026-06-15 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 15,414 | 8.99 | $138,572 | 16,638,150 | Form 4 |
| 2026-06-12 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 391,019 | 8.57 | $3.35M | 16,622,736 | Form 4 |
| 2026-06-11 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 548,580 | 7.91 | $4.34M | 16,231,717 | Form 4 |
| 2026-06-10 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 103 | 7.00 | $721 | 15,683,137 | Form 4 |
| 2026-06-09 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 479,039 | 6.91 | $3.31M | 15,683,034 | Form 4 |
| 2026-05-19 | Aslan FredDirector, Chief Executive Officer | Sale | 27,116 | 9.01 | $244,315 | 1,535,082 | Form 4 |
| 2026-05-19 | Banerjee SubhashisChief Medical Officer | Sale | 7,037 | 9.01 | $63,403 | 144,963 | Form 4 |
| 2026-05-19 | Bush JenniferCOO, CLO, Compliance Officer | Sale | 8,790 | 9.01 | $79,198 | 337,920 | Form 4 |
| 2026-05-19 | Horan ChristopherChief Tech Operations Officer | Sale | 7,002 | 9.01 | $63,088 | 293,450 | Form 4 |
| 2026-05-19 | Raymon HeatherSVP, Research and Development | Sale | 3,095 | 9.01 | $27,886 | 148,228 | Form 4 |
| 2026-05-11 | Gc Corp.10% ownerwith Gc Cell Corp | Buy | 1,085,069 | 11.52 | $12.50M | 4,391,969 | Form 4 |
| 2026-05-11 | Gc Corp.10% ownerwith Gc Cell Corp | Buyindirect | 347,222 | 11.52 | $4.00M | 1,607,734 | Form 4 |
| 2026-05-11 | Ra Capital Healthcare Fund LPDirector, 10% ownerwith Ra Capital Management, L.P., Kolchinsky Peter, Shah Rajeev M., Ra Capital Nexus Fund, L.P., Ra Capital Nexus Fund III, L.P. | Buyindirect | 6,510,416 | 11.52 | $75.00M | 15,203,995 | Form 4 |
| 2025-12-15 | Aslan FredDirector, President and CEO | Saleplan | 3,187 | 6.00 | $19,122 | 1,209,948 | Form 4 |
| 2025-11-17 | Aslan FredDirector, President and CEO | Saleplan | 6,375 | 3.38 | $21,548 | 343,999 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
24 × grant or award19 × shares withheld for tax2 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Aslan FredDirector, Chief Executive Officer | Grant or award A | +110,000 | – | 1,604,765 | Form 4 |
| 2026-09-10 | Aslan FredDirector, Chief Executive Officer | Grant or award A | +45,000 | – | 1,494,765 | Form 4 |
| 2026-09-09 | Banerjee SubhashisChief Medical Officer | Grant or award A | +30,000 | – | 170,947 | Form 4 |
| 2026-09-09 | Bush JenniferCOO, CLO, Compliance Officer | Grant or award A | +45,000 | – | 374,529 | Form 4 |
| 2026-09-09 | Horan ChristopherChief Tech Operations Officer | Grant or award A | +40,000 | – | 323,084 | Form 4 |
| 2026-09-09 | Miralles Gines DiegoPresident & Head of R&D | Grant or award A | +45,000 | – | 122,500 | Form 4 |
| 2026-08-27 | Banerjee SubhashisChief Medical Officer | Option exercise M | +5,306 | 1.92 | 150,269 | Form 4 |
| 2026-08-18 | Banerjee SubhashisChief Medical Officer | Option exercise M | +429 | 1.92 | 145,392 | Form 4 |
| 2026-05-18 | Miralles Gines DiegoPresident & Head of R&D | Grant or award A | +77,500 | – | 77,500 | Form 4 |
| 2026-03-10 | Huston Thad AllenChief Financial Officer | Grant or award A | +220,000 | – | 220,000 | Form 4 |
| 2026-02-15 | Aslan FredDirector, President and CEO | Grant or award A | +366,850 | – | 1,576,798 | Form 4 |
| 2026-02-15 | Aslan FredDirector, President and CEO | Shares withheld for tax F | −14,600 | 4.00 | 1,562,198 | Form 4 |
| 2026-02-15 | Banerjee SubhashisChief Medical Officer | Grant or award A | +102,000 | – | 152,000 | Form 4 |
| 2026-02-15 | Bush JenniferCOO, CLO, Secy, Compliance Off | Grant or award A | +117,300 | – | 350,225 | Form 4 |
| 2026-02-15 | Bush JenniferCOO, CLO, Secy, Compliance Off | Shares withheld for tax F | −3,515 | 4.00 | 346,710 | Form 4 |
| 2026-02-15 | Horan ChristopherChief Tech Operations Officer | Grant or award A | +117,300 | – | 302,639 | Form 4 |
| 2026-02-15 | Horan ChristopherChief Tech Operations Officer | Shares withheld for tax F | −2,187 | 4.00 | 300,452 | Form 4 |
| 2026-02-15 | Raymon HeatherSVP, Research and Development | Grant or award A | +46,000 | – | 152,844 | Form 4 |
| 2026-02-15 | Raymon HeatherSVP, Research and Development | Shares withheld for tax F | −1,521 | 4.00 | 151,323 | Form 4 |
| 2025-12-12 | Aslan FredDirector, President and CEO | Grant or award A | +869,136 | – | 1,213,135 | Form 4 |
| 2025-12-12 | Bush JenniferCOO, CLO, Secy, Compliance Off | Grant or award A | +84,877 | – | 232,925 | Form 4 |
| 2025-12-12 | Horan ChristopherChief Tech Operations Officer | Grant or award A | +107,156 | – | 185,339 | Form 4 |
| 2025-12-12 | Raymon HeatherSVP, Research and Development | Grant or award A | +67,253 | – | 106,844 | Form 4 |
| 2025-11-15 | Aslan FredDirector, President and CEO | Shares withheld for tax F | −6,347 | 3.25 | 350,374 | Form 4 |
| 2025-11-15 | Krishnamohan NehaChief Financial Officer | Shares withheld for tax F | −3,490 | 3.25 | 99,356 | Form 4 |
| 2025-11-15 | Bush JenniferCOO, CLO, Secy, Compliance Off | Shares withheld for tax F | −3,055 | 3.25 | 148,048 | Form 4 |
| 2025-11-15 | Horan ChristopherChief Tech Operations Officer | Shares withheld for tax F | −1,899 | 3.25 | 78,183 | Form 4 |
| 2025-11-15 | Raymon HeatherSVP, Research and Development | Shares withheld for tax F | −1,375 | 3.25 | 39,591 | Form 4 |
| 2025-08-15 | Horan ChristopherChief Tech Operations Officer | Shares withheld for tax F | −3,577 | 2.75 | 80,082 | Form 4 |
| 2025-08-15 | Bush JenniferCOO, CLO, Secy, Compliance Off | Shares withheld for tax F | −6,409 | 2.75 | 151,103 | Form 4 |
| 2025-08-15 | Krishnamohan NehaChief Financial Officer | Shares withheld for tax F | −5,813 | 2.75 | 102,846 | Form 4 |
| 2025-08-15 | Raymon HeatherSVP, Research and Development | Shares withheld for tax F | −1,639 | 2.75 | 40,966 | Form 4 |
| 2025-08-15 | Aslan FredDirector, President and CEO | Shares withheld for tax F | −4,472 | 2.75 | 382,221 | Form 4 |
| 2025-05-15 | Horan ChristopherChief Tech Operations Officer | Shares withheld for tax F | −1,341 | 2.13 | 83,659 | Form 4 |
| 2025-05-15 | Bush JenniferCOO, CLO, Secy, Compliance Off | Shares withheld for tax F | −1,937 | 2.13 | 157,512 | Form 4 |
| 2025-05-15 | Krishnamohan NehaChief Financial Officer | Shares withheld for tax F | −1,341 | 2.13 | 108,659 | Form 4 |
| 2025-05-15 | Raymon HeatherSVP, Research and Development | Shares withheld for tax F | −745 | 2.13 | 42,605 | Form 4 |
| 2025-05-15 | Aslan FredDirector, President and CEO | Shares withheld for tax F | −4,472 | 2.13 | 412,193 | Form 4 |
| 2025-04-08 | Banerjee SubhashisChief Medical Officer | Grant or award A | +50,000 | – | 50,000 | Form 4 |
| 2025-03-05 | Aslan FredDirector, President and CEO | Grant or award A | +200,000 | – | 416,665 | Form 4 |
| 2025-02-26 | Bush JenniferCOO, CLO, Secy, Compliance Off | Grant or award A | +86,650 | – | 159,449 | Form 4 |
| 2025-02-26 | Krishnamohan NehaChief Financial Officer | Grant or award A | +60,000 | – | 110,000 | Form 4 |
| 2025-02-26 | Horan ChristopherChief Tech Operations Officer | Grant or award A | +60,000 | – | 85,000 | Form 4 |
| 2025-02-26 | Graef ThorstenChief Medical Officer | Grant or award A | +60,000 | – | 80,000 | Form 4 |
| 2025-02-26 | Raymon HeatherSVP, Research and Development | Grant or award A | +33,350 | – | 43,350 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.